share_log

The IPO Market Is On Fire With Another Record Week Ahead

The IPO Market Is On Fire With Another Record Week Ahead

IPO市場火爆,未來一週將再創新高
Benzinga Real-time News ·  2021/07/27 10:46

After another week of record activity, the IPO market will be even hotter with 25 scheduled IPOs this week. If all scheduled IPOs begin trading as expected, this will be the busiest week for the US IPO market in more than two decades.

在經歷了又一週的創紀錄活動後,IPO市場將更加火爆,本週將有25宗預定IPO。如果所有預定的IPO都像預期的那樣開始交易,這將是美國IPO市場20多年來最繁忙的一週。

Vehicle low-voltage battery maker profitable on an EBIT basis, Clarios International (NYSE:BTRY) plans to raise $1.7 billion at a $9.7 billion market cap. After negative revenue growth last year due to the pandemic, revenue growth has accelerated during the first half of 2021.

車輛低壓電池製造商在息税前利潤的基礎上,克拉裏奧斯國際(紐約證券交易所:BTRY)計劃以97億美元的市值籌集17億美元。在去年因疫情而出現收入負增長之後,2021年上半年收入增長加快。

A profitable cloud-based programmatic digital advertising platform that provides monetization services to about 3,100 publishers, Teads (NASDAQ:TEAD) plans to raise $751 million at a $4.6 billion market cap.

Teads是一個盈利的基於雲的程序化數字廣告平臺,為大約3100家出版商提供貨幣化服務(NASDAQ:Tead)計劃以46億美元的市值籌集7.51億美元。

Provider of an education platform that enables teachers to manage their virtual classrooms such as collective work and grade assignments, PowerSchool Holdings (NYSE:PWSC) plans to raise $750 million at a $3.7 billion market cap. It served 12,000 customers across 90 countries, becoming profitable on a net income basis during the first half of 2021.

提供一個教育平臺,使教師能夠管理他們的虛擬教室,如集體作業和成績作業,PowerSchool控股公司紐約證券交易所代碼:PWSC)計劃以37億美元的市值籌集7.5億美元。它為90個國家的1.2萬名客户提供了服務,2021年上半年在淨收入的基礎上實現了盈利。

After withdrawing from its public debut in 2018, a leading, profitable, and slow-growing fruit and vegetable company offering 300 products sourced from over 30 countries to over 80 countries across the globe, Dole (NYSE:DOLE) plans to raise $559 million this time around, at a $2 billion market cap.

在2018年退出公開上市後,一家領先的、盈利的、增長緩慢的水果和蔬菜公司提供了300種產品,這些產品來自30多個國家,銷往全球80多個國家。失業救濟金紐約證券交易所代碼:失業救濟金)計劃這一次籌資5.59億美元,市值20億美元。

Language learning platform that educated over 300 million users, Duolingo (NASDAQ:DUOL) plans to raise $460 million at a $4.1 billion market cap. The pandemic fueled triple-digit growth last year.

語言學習平臺,教育了超過3億用户,多林戈(納斯達克:DUOL)計劃以41億美元的市值籌集4.6億美元。去年,這場大流行推動了三位數的增長。

Manufacturer of premium grills that can be controlled via an app, Traeger (NYSE:COOK) plans to raise $400 million at a $2.2 billion market cap.

可以通過應用程序控制的高級燒烤架製造商,特雷格紐約證券交易所代碼:)計劃以22億美元的市值籌集4億美元。

Growing but unprofitable Riskified (NYSE:RSKD) provides e-commerce fraud protection for enterprises, plans to raise $333 million on July 29th. FCF was positive over the first quarter of 2021.

增長但無利可圖的Riskized(紐約證券交易所:RSKD)為企業提供電商詐騙保護,計劃7月29日融資3.33億美元。FCF在2021年第一季度為正。

Financial software provider for mid-market community banks and credit unions, MeridianLink (NYSE:MLNK), plans to raise $300 million at a $2.1 billion market cap. The nature of its business is cyclical, but strong mortgage activity enabled double-digit organic growth.

面向中端市場社區銀行和信用社的金融軟件提供商子午線紐約證券交易所代碼:MLNK),計劃以21億美元的市值籌集3億美元。其業務性質是週期性的,但強勁的抵押貸款活動使其實現了兩位數的有機增長。

Smart home integration system that demonstrated solid growth and profitability on EBIT basis, Snap One Holdings (NASDAQ:SNPO), plans to raise $270 million at a $1.5 billion market cap.

智能家居集成系統在息税前利潤的基礎上表現出穩健的增長和盈利能力,Snap One Holdings(納斯達克:SNPO),計劃以15億美元的市值籌集2.7億美元。

Specialty funding solutions provider for projects of significant social and economic importance to local communities in the US, Preston Hollow Community Capital (NYSE:PHCC), plans to raise $200 million at a $2.3 billion market cap.

為對美國當地社區具有重大社會和經濟意義的項目提供專業融資解決方案,普雷斯頓霍洛社區資本紐約證券交易所代碼:PHCC),計劃以23億美元的市值籌集2億美元。

Oncology biotech Nuvalent (NYSE:NUVL) plans to raise $151 million at an $835 million market cap. Its lead candidate treats ROS1-positive non-small cell lung cancer and other advanced solid tumors, with trials expected to begin by year-end.

腫瘤學生物技術核價紐約證券交易所代碼:NUVL)計劃以8.35億美元的市值籌集1.51億美元。它的主要候選藥物是治療ROS1陽性的非小細胞肺癌和其他晚期實體腫瘤,預計試驗將於年底開始。

AIM-listed cell engineering platform MaxCyte (NASDAQ:MXCT) plans to raise $150 million at a $1.3 billion market cap. Its flagship product can be used across the rapidly expanding cell therapy sector.

在AIM上市的細胞工程平臺MaxCyte(納斯達克:MXCT)計劃以13億美元的市值籌集1.5億美元。其旗艦產品可用於快速擴張的細胞治療領域。

A clinical stage vaccine biotech Icosavax (NASDAQ:ICVX) plans to raise $150 million at a $590 million market cap. This biotech is focused on developing vaccines against infectious respiratory diseases using its virus-like particle platform technology, with its most advanced candidate aimed at SARS-CoV-2 currently in a Phase 1/2 trial.

一種臨牀階段疫苗生物技術Icosavax(納斯達克:ICVX)計劃以5.9億美元的市值籌集1.5億美元。這項生物技術專注於利用其類似病毒的顆粒平臺技術開發針對傳染性呼吸道疾病的疫苗,其最先進的候選疫苗針對SARS-CoV-2目前處於1/2階段試驗。

Genetic and non-genetic heart disease biotech Tenaya Therapeutics (NASDAQ:TNYA) plans to raise $150 million at a $585 million market cap. It has three programs: gene therapy, cellular regeneration, and precision medicine. INDs submission is planned for 2022.

遺傳性和非遺傳性心臟病生物技術天谷治療公司(Tenaya Treateutics)(納斯達克:TNYA)計劃以5.85億美元的市值籌集1.5億美元。它有三個項目:基因治療、細胞再生和精確醫學。INDS提交計劃於2022年提交。

Gene therapy biotech in preclinical stage spanning across regenerative medicine and multigenic diseases, Omega Therapeutics (NASDAQ:OMGA) plans to raise $126 million at an $866 million market cap.

橫跨再生醫學和多基因疾病的臨牀前階段的基因治療生物技術,歐米茄治療公司(NASDAQ:OMGA)計劃以8.66億美元的市值籌集1.26億美元。

RxSight (NASDAQ:RXST) is developing the first and only commercially available intraocular lens technology to enables doctors to customize and optimize visual acuity after a patient undergoes cataract surgery. It plans to raise $125 million, aiming for a $477 million market cap.

RxSight(納斯達克:RXST)正在開發第一項也是唯一一項商業化的人工晶狀體技術,使醫生能夠在患者接受白內障手術後定製和優化視力。它計劃籌集1.25億美元,目標是市值達到4.77億美元。

Oncology biotech Immuneering (NASDAQ:IMRX) plans to raise $105 million at a $391 million market cap. Its flagship program is aimed to treat advanced solid tumor patients harboring RAS mutant tumors. The company plans to submit its first IND next year and anticipates filings at least two additional INDs in 2023 and 2024.

腫瘤學生物技術免疫接種(納斯達克:IMRX)計劃以3.91億美元的市值籌集1.05億美元。其旗艦計劃旨在治療攜帶RAS突變腫瘤的晚期實體腫瘤患者。該公司計劃明年提交第一份IND,預計在2023年和2024年至少再提交兩份IND申請。

Rani Therapeutics  (NASDAQ:RANI) aims to replace subcutaneous or IV injections with oral dosing plans to raise $100 million at a $724 million market cap. The RaniPill capsule is a novel, proprietary, and patented platform technology.

拉尼治療公司(納斯達克:拉尼)旨在用口服劑量計劃取代皮下或靜脈注射,以7.24億美元的市值籌集1億美元。RaniPill膠囊是一種新穎的、專有的、獲得專利的平臺技術。

A biotech focused on treating cancer, Candel Therapeutics (NASDAQ:CADL) hopes to raise $85 million. Its most advanced candidate is currently in a Phase 3 trial for newly diagnosed localized prostate cancer with an intermediate or high risk for progression.

一種專注於治療癌症的生物技術,秋茄治療公司(納斯達克:CADL)希望籌集8500萬美元。它最先進的候選藥物目前正處於新診斷的中高進展風險的局部性前列腺癌的3期試驗中。

Rare disease clinical-stage biotech Rallybio (NASDAQ:RLYB) plans to raise $81 million at a $465 million market cap. Its lead program aimed to treat fetal and neonatal alloimmune thrombocytopenia is currently in Phase 1/2 trial.

罕見疾病臨牀期生物技術Rallybio(納斯達克:RLYB)計劃以4.65億美元的市值籌集8100萬美元。它的主要項目旨在治療胎兒和新生兒同種異體免疫性血小板減少症,目前正處於1/2期試驗。

Ocean Biomedical (NASDAQ:OCEA) is pursuing preclinical programs in oncology, fibrosis, infectious disease, and inflammation that have been licensed from Brown University, Stanford University, and Rhode Island Hospital aims to raise $50 million.

海洋生物醫學(納斯達克:屋宇)正在開展腫瘤學、纖維化、傳染病和炎症等臨牀前項目,這些項目已獲得布朗大學、斯坦福大學和羅德島醫院的許可,計劃籌集5000萬美元。

After postponing its public debut last November, IN8bio (NASDAQ:INAB) plans to raise $44 million at a $215 million market cap. This Phase 1 biotech is developing cell therapies to treat solid tumors.

在去年11月推遲公開亮相後,IN8Bio(納斯達克:INAB)計劃以2.15億美元的市值籌集4400萬美元。這一階段的生物技術正在開發治療實體腫瘤的細胞療法。

A profitable Chinese organic fertilizer producer Muliang Viagoo (NASDAQ:MULG) is aiming for a market cap of $194 million, hoping to raise $40 million.

一家盈利的中國有機肥生產商木良偉哥(納斯達克:MULG)的目標是市值1.94億美元,希望籌集4,000萬美元。

Biotech aimed at curing female cancer, Context Therapeutics (NASDAQ:CNTX) plans to raise $20 million at a $93 million market cap. Its lead candidate is currently in Phase 2 trials for ovarian and endometrial cancer.

旨在治癒女性癌症的生物技術,情境治療學(納斯達克:CNTX)計劃以9300萬美元的市值籌集2000萬美元。它的主要候選藥物目前正在卵巢癌和子宮內膜癌的第二階段試驗中。

This article is not a press release and is contributed by a verified independent journalist for IAMNewswire. It should not be construed as investment advice at any time please read the full disclosure. IAM Newswire does not hold any position in the mentioned companies. Press Releases – If you are looking for full Press release distribution contact: press@iamnewswire.com Contributors – IAM Newswire accepts pitches. If you're interested in becoming an IAM journalist contact: contributors@iamnewswire.com

本文不是新聞稿,由IAMNewswire的一位經過驗證的獨立記者貢獻。任何時候都不應將其理解為投資建議,請閲讀全文披露。IAM Newswire在上述公司沒有任何職位。新聞稿-如果您正在尋找完整的新聞稿分發聯繫人:電子郵件:press@iamnewswre.com撰稿人-IAM Newswire接受推介。如果您有興趣成為一名IAM記者,請聯繫:郵箱:Contributors@iamnewswre.com

Image by Free-Photos from Pixabay

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論